TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies

DISCO Pharmaceuticals announced an exclusive license agreement with Amgen for a cancer cell surface target discovered using DISCO's proprietary surfaceome mapping technology. DISCO is eligible to receive up to $618 million in total potential deal value plus royalties, while Amgen receives exclusive global rights to develop and commercialize the resulting therapeutic programs.

Insights
CTSH   positive

Already rolling out AI to clients and internally, positioned as an IT services firm with AI integration


AMGN   positive

Amgen gained exclusive global rights to develop and commercialize novel cancer therapeutics from a validated technology platform, expanding their oncology pipeline with potentially differentiated bispecific ADCs and T-cell engagers for hard-to-treat tumors.